Legislation

Requiring, on or before March 31 each year, the manufacturer of an expensive drug sold or offered for sale in the State to file with the Secretary of Health and Mental Hygiene a specified annual report; establishing the Drug Price Transparency Advisory Committee; requiring a manufacturer of an expensive drug to file a notice with the Secretary before increasing a specified price or a specified cost by more than a specified percentage or amount during specified periods of time; etc.

Committees

Original:: Health and Government Operations Click to view Recorded Media

Details

Cross-filed with: SB0437

Bill File Type: Regular

Effective Date(s): October 1, 2017

History

Legislation History
Chamber House Calendar Date 2/01/2017 Legislative Date 2/01/2017 Action First Reading Health and Government Operations Proceedings
Chamber Calendar Date Legislative Date Action Text - First - Public Health - Expensive Drugs - Manufacturer Reporting and Drug Price Transparency Advisory Committee Proceedings
Chamber House Calendar Date 2/08/2017 Legislative Date 2/08/2017 Action Hearing 2/23 at 1:00 p.m. Proceedings

Chamber	Calendar Date	Legislative Date	Action
House	2/01/2017	2/01/2017	First Reading Health and Government Operations
			Text - First - Public Health - Expensive Drugs - Manufacturer Reporting and Drug Price Transparency Advisory Committee
House	2/08/2017	2/08/2017	Hearing 2/23 at 1:00 p.m.

File Code

Subjects

Statutes